|
1
|
Ginsburg O, Bray F, Coleman MP, Vanderpuye
V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et
al: The global burden of women's cancers: A grand challenge in
global health. Lancet. 389:847–860. 2017. View Article : Google Scholar
|
|
2
|
GLOBOCAN, . 2020.New global cancer data.
https://www.uicc.org/news/globocan-2020-new-global-cancer-dataNovember
24–2021
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
|
|
4
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar
|
|
5
|
Hall CS, Valad L and Lucci A: Circulating
tumor cells in breast cancer patients. Crit Rev Oncog. 21:125–139.
2016. View Article : Google Scholar
|
|
6
|
Green M and Hortobagyi GN: Neoadjuvant
chemotherapy for operable breast cancer. Oncology (Williston Park).
16:871–884. 889–890. 892–904. 997–998. 2002.
|
|
7
|
Fisher B, Bauer M, Wickerham DL, Redmond
CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R,
et al: Relation of number of positive axillary nodes to the
prognosis of patients with primary breast cancer. An NSABP update.
Cancer. 52:1551–1557. 1983. View Article : Google Scholar
|
|
8
|
Gilbey AM, Burnett D, Coleman RE and Holen
I: The detection of circulating breast cancer cells in blood. J
Clin Pathol. 57:903–911. 2004. View Article : Google Scholar
|
|
9
|
Cueva Bañuelos JF, Rodríguez López C,
Cortegoso Mosquera A, Palacios Ozores P and Curiel García T:
Clinical relevance and therapeutic application of CTCs in advanced
breast cancer. Adv Exp Med Biol. 1220:147–164. 2020. View Article : Google Scholar
|
|
10
|
Cardoso F, Spence D, Mertz S,
Corneliussen-James D, Sabelko K, Gralow J, Cardoso MJ, Peccatori F,
Paonessa D, Benares A, et al: Global analysis of
advanced/metastatic breast cancer: Decade report (2005–2015).
Breast. 39:131–138. 2018. View Article : Google Scholar
|
|
11
|
Weiss L: Metastasis of cancer: A
conceptual history from antiquity to the 1990s. Cancer Metastasis
Rev. 19:193–383. 2000. View Article : Google Scholar
|
|
12
|
Wittekind C and Neid M: Cancer invasion
and metastasis. Oncology. 69 (Suppl 1):S14–S16. 2005. View Article : Google Scholar
|
|
13
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004. View Article : Google Scholar
|
|
14
|
Giuliano M, Giordano A, Jackson S, De
Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, et
al: Circulating tumor cells as early predictors of metastatic
spread in breast cancer patients with limited metastatic
dissemination. Breast Cancer Res. 16:4402014. View Article : Google Scholar
|
|
15
|
Ignatiadis M, Kallergi G, Ntoulia M,
Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E,
Lianidou E, Georgoulias V and Mavroudis D: Prognostic value of the
molecular detection of circulating tumor cells using a multimarker
reverse transcription-PCR assay for cytokeratin 19, mammaglobin A,
and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600.
2008. View Article : Google Scholar
|
|
16
|
Lucci A, Hall CS, Lodhi AK, Bhattacharyya
A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM and Krishnamurthy S:
Circulating tumour cells in non-metastatic breast cancer: A
prospective study. Lancet Oncol. 13:688–695. 2012. View Article : Google Scholar
|
|
17
|
Zhang L, Riethdorf S, Wu G, Wang T, Yang
K, Peng G, Liu J and Pantel K: Meta-analysis of the prognostic
value of circulating tumor cells in breast cancer. Clin Cancer Res.
18:5701–5710. 2012. View Article : Google Scholar
|
|
18
|
Enderling H, Hlatky L and Hahnfeldt P:
Migration rules: Tumours are conglomerates of self-metastases. Br J
Cancer. 100:1917–1925. 2009. View Article : Google Scholar
|
|
19
|
Kim MY, Oskarsson T, Acharyya S, Nguyen
DX, Zhang XH, Norton L and Massagué J: Tumor self-seeding by
circulating cancer cells. Cell. 139:1315–1326. 2009. View Article : Google Scholar
|
|
20
|
Pantel K and Speicher MR: The biology of
circulating tumor cells. Oncogene. 35:1216–1224. 2016. View Article : Google Scholar
|
|
21
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–889.
2012. View Article : Google Scholar
|
|
22
|
Bae SY, Kamalanathan KJ, Galeano-Garces C,
Konety BR, Antonarakis ES, Parthasarathy J, Hong J and Drake JM:
Dissemination of circulating tumor cells in breast and prostate
cancer: Implications for early detection. Endocrinology.
165:bqae0222024. View Article : Google Scholar
|
|
23
|
Alix-Panabières C and Pantel K: Challenges
in circulating tumour cell research. Nat Rev Cancer. 14:623–631.
2014. View Article : Google Scholar
|
|
24
|
Coumans FAW, Ligthart ST, Uhr JW and
Terstappen LWMM: Challenges in the enumeration and phenotyping of
CTC. Clin Cancer Res. 18:5711–5718. 2012. View Article : Google Scholar
|
|
25
|
Mego M and Reuben JM: Prognostic and
predictive role of circulating tumor cells in breast cancer. Curr
Breast Cancer Rep. 6:251–259. 2014. View Article : Google Scholar
|
|
26
|
Kanwar N and Done SJ: Molecular profiling
and significance of circulating tumor cell based genetic
signatures. Adv Exp Med Biol. 994:143–167. 2017. View Article : Google Scholar
|
|
27
|
Mego M, Mani SA and Cristofanilli M:
Molecular mechanisms of metastasis in breast cancer-clinical
applications. Nat Rev Clin Oncol. 7:693–701. 2010. View Article : Google Scholar
|
|
28
|
Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang
D, Luo D, Huang Y, Feng Y and Wang N: Circulating tumor cells in
the early detection of human cancers. Int J Biol Sci. 18:3251–3265.
2022. View Article : Google Scholar
|
|
29
|
Ju S, Chen C, Zhang J, Xu L, Zhang X, Li
Z, Chen Y, Zhou J, Ji F and Wang L: Detection of circulating tumor
cells: Opportunities and challenges. Biomark Res. 10:582022.
View Article : Google Scholar
|
|
30
|
Cristofanilli M: Circulating tumor cells,
disease progression, and survival in metastatic breast cancer.
Semin Oncol. 33 (3 Suppl 9):S9–S14. 2006. View Article : Google Scholar
|
|
31
|
Cristofanilli M, Hayes DF, Budd GT, Ellis
MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC,
et al: Circulating tumor cells: A novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin oncol. 23:1420–1430.
2005. View Article : Google Scholar
|
|
32
|
Alix-Panabières C and Pantel K: Clinical
applications of circulating tumor cells and circulating tumor DNA
as liquid biopsy. Cancer Discov. 6:479–491. 2016. View Article : Google Scholar
|
|
33
|
Lianidou ES and Markou A: Circulating
tumor cells in breast cancer: Detection systems, molecular
characterization, and future challenges. Clin Chem. 57:1242–1255.
2011. View Article : Google Scholar
|
|
34
|
Andree KC, van Dalum G and Terstappen
LWMM: Challenges in circulating tumor cell detection by the
CellSearch system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar
|
|
35
|
Müller V, Riethdorf S, Rack B, Janni W,
Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K and
Fehm T; DETECT study group, : Prognostic impact of circulating
tumor cells assessed with the CellSearch system™ and
AdnaTest breast™ in metastatic breast cancer patients:
The DETECT study. Breast Cancer Res. 14:R1182012. View Article : Google Scholar
|
|
36
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View Article : Google Scholar
|
|
37
|
Danila DC, Samoila A, Patel C, Schreiber
N, Herkal A, Anand A, Bastos D, Heller G, Fleisher M and Scher HI:
Clinical validity of detecting circulating tumor cells by AdnaTest
assay compared with direct detection of tumor mrna in stabilized
whole blood, as a biomarker predicting overall survival for
metastatic castration-resistant prostate cancer patients. Cancer J.
22:315–320. 2016. View Article : Google Scholar
|
|
38
|
Gorges TM, Stein A, Quidde J, Hauch S,
Röck K, Riethdorf S, Joosse SA and Pantel K: Improved detection of
circulating tumor cells in metastatic colorectal cancer by the
combination of the CellSearch® system and the
AdnaTest®. PLoS One. 11:e01551262016. View Article : Google Scholar
|
|
39
|
Talasaz AH, Powell AA, Huber DE, Berbee
JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, et al:
Isolating highly enriched populations of circulating epithelial
cells and other rare cells from blood using a magnetic sweeper
device. Proc Natl Acad Sci USA. 106:3970–3975. 2009. View Article : Google Scholar
|
|
40
|
Harb W, Fan A, Tran T, Danila DC, Keys D,
Schwartz M and Ionescu-Zanetti C: Mutational analysis of
circulating tumor cells using a novel microfluidic collection
device and qPCR assay. Transl Oncol. 6:528–538. 2013. View Article : Google Scholar
|
|
41
|
Cho H, Kim J, Jeon CW and Han KH: A
disposable microfluidic device with a reusable magnetophoretic
functional substrate for isolation of circulating tumor cells. Lab
Chip. 17:4113–4123. 2017. View Article : Google Scholar
|
|
42
|
Liu Z, Fusi A, Klopocki E, Schmittel A,
Tinhofer I, Nonnenmacher A and Keilholz U: Negative enrichment by
immunomagnetic nanobeads for unbiased characterization of
circulating tumor cells from peripheral blood of cancer patients. J
Transl Med. 9:702011. View Article : Google Scholar
|
|
43
|
Naume B, Borgen E, Tøssvik S, Pavlak N,
Oates D and Nesland JM: Detection of isolated tumor cells in
peripheral blood and in BM: Evaluation of a new enrichment method.
Cytotherapy. 6:244–252. 2004. View Article : Google Scholar
|
|
44
|
Habli Z, AlChamaa W, Saab R, Kadara H and
Khraiche ML: Circulating tumor cell detection technologies and
clinical utility: Challenges and opportunities. Cancers (Basel).
12:19302020. View Article : Google Scholar
|
|
45
|
Tong B, Xu Y, Zhao J, Chen M, Xing J,
Zhong W and Wang M: Prognostic significance of circulating tumor
cells in non-small cell lung cancer patients undergoing
chemotherapy. Oncotarget. 8:86615–86624. 2017. View Article : Google Scholar
|
|
46
|
Drucker A, Teh EM, Kostyleva R, Rayson D,
Douglas S and Pinto DM: Comparative performance of different
methods for circulating tumor cell enrichment in metastatic breast
cancer patients. PLoS One. 15:e02373082020. View Article : Google Scholar
|
|
47
|
Mego M, Mani SA, Lee BN, Li C, Evans KW,
Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, et al:
Expression of epithelial-mesenchymal transition-inducing
transcription factors in primary breast cancer: The effect of
neoadjuvant therapy. Int J Cancer. 130:808–816. 2012. View Article : Google Scholar
|
|
48
|
Vona G, Sabile A, Louha M, Sitruk V,
Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, et
al: Isolation by size of epithelial tumor cells: A new method for
the immunomorphological and molecular characterization of
circulatingtumor cells. Am J Pathol. 156:57–63. 2000. View Article : Google Scholar
|
|
49
|
Dolfus C, Piton N, Toure E and Sabourin
JC: Circulating tumor cell isolation: The assets of filtration
methods with polycarbonate track-etched filters. Chin J Cancer Res.
27:479–487. 2015.
|
|
50
|
Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo
RA, Tan DS, Lim WT, Han J, Bhagat AA and Lim CT: Isolation and
retrieval of circulating tumor cells using centrifugal forces. Sci
Rep. 3:12592013. View Article : Google Scholar
|
|
51
|
Tamminga M, Andree KC, Hiltermann TJN,
Jayat M, Schuuring E, van den Bos H, Spierings DCJ, Lansdorp PM,
Timens W, Terstappen LWMM and Groen HJM: Detection of circulating
tumor cells in the diagnostic leukapheresis product of
non-small-cell lung cancer patients comparing
CellSearch® and ISET. Cancers (Basel). 12:8962020.
View Article : Google Scholar
|
|
52
|
Miller MC, Robinson PS, Wagner C and
O'Shannessy DJ: The parsortix™ cell separation system-A
versatile liquid biopsy platform. Cytometry A. 93:1234–1239. 2018.
View Article : Google Scholar
|
|
53
|
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa
K, Berney D, Cathcart P, Hines J, Shamash J and Lu YJ: Optimization
and evaluation of a novel size based circulating tumor cell
isolation system. PLoS One. 10:e01380322015. View Article : Google Scholar
|
|
54
|
Bankó P, Lee SY, Nagygyörgy V, Zrínyi M,
Chae CH, Cho DH and Telekes A: Technologies for circulating tumor
cell separation from whole blood. J Hematol Oncol. 12:482019.
View Article : Google Scholar
|
|
55
|
Rosenberg R, Gertler R, Friederichs J,
Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H and Siewert JR:
Comparison of two density gradient centrifugation systems for the
enrichment of disseminated tumor cells in blood. Cytometry.
49:150–158. 2002. View Article : Google Scholar
|
|
56
|
Lagoudianakis EE, Kataki A, Manouras A,
Memos N, Papadima A, Derventzi A, Zografos G, Papadopoulos S,
Katergiannakis V and Konstadoulakis MM: Detection of epithelial
cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal
carcinoma patients using OncoQuick density gradient centrifugation
system. J Surg Res. 155:183–190. 2009. View Article : Google Scholar
|
|
57
|
Gupta V, Jafferji I, Garza M, Melnikova
VO, Hasegawa DK, Pethig R and Davis DW: ApoStream(™), a
new dielectrophoretic device for antibody independent isolation and
recovery of viable cancer cells from blood. Biomicrofluidics.
6:241332012. View Article : Google Scholar
|
|
58
|
O'Shannessy DJ, Davis DW, Anderes K and
Somers EB: Isolation of circulating tumor cells from multiple
epithelial cancers with ApoStream(®) for detecting (or
monitoring) the expression of Folate receptor alpha. Biomark
Insights. 11:7–18. 2016. View Article : Google Scholar
|
|
59
|
Le Du F, Fujii T, Kida K, Davis DW, Park
M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, et al:
EpCAM-independent isolation of circulating tumor cells with
epithelial-to-mesenchymal transition and cancer stem cell
phenotypes using ApoStream® in patients with breast
cancer treated with primary systemic therapy. PLoS One.
15:e02299032020. View Article : Google Scholar
|
|
60
|
Wu S, Gu L, Qin J, Zhang L, Sun F, Liu Z,
Wang Y and Shi D: Rapid label-free isolation of circulating tumor
cells from patients' peripheral blood using electrically charged
Fe3O4 nanoparticles. ACS Appl Mater
Interfaces. 12:4193–4203. 2020. View Article : Google Scholar
|
|
61
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar
|
|
62
|
Luc R, Tortorella SM, Ververis K and
Karagiannis TC: Lactate as an insidious metabolite due to the
Warburg effect. Mol Biol Rep. 42:835–840. 2015. View Article : Google Scholar
|
|
63
|
Zhu Z and Zhang YHP: In vitro metabolic
engineering of bioelectricity generation by the complete oxidation
of glucose. Metab Eng. 39:110–116. 2017. View Article : Google Scholar
|
|
64
|
Nasiri R, Shamloo A, Ahadian S, Amirifar
L, Akbari J, Goudie MJ, Lee K, Ashammakhi N, Dokmeci MR, Di Carlo D
and Khademhosseini A: Microfluidic-based approaches in targeted
cell/particle separation based on physical properties:
Fundamentalsand applications. Small. 16:e20001712020. View Article : Google Scholar
|
|
65
|
Burinaru TA, Avram M, Avram A, Mărculescu
C, Ţîncu B, Ţucureanu V, Matei A and Militaru M: Detection of
circulating tumor cells using microfluidics. ACS Comb Sci.
20:107–126. 2018. View Article : Google Scholar
|
|
66
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar
|
|
67
|
Park MH, Reátegui E, Li W, Tessier SN,
Wong KH, Jensen AE, Thapar V, Ting D, Toner M, Stott SL and Hammond
PT: Enhanced isolation and release of circulating tumor cells using
nanoparticle binding and ligand exchange in a microfluidic chip. J
Am Chem Soc. 139:2741–2749. 2017. View Article : Google Scholar
|
|
68
|
Zhang X, Zhu Z, Xiang N, Long F and Ni Z:
Automated microfluidic instrument for label-free and
high-throughput cell separation. Anal Chem. 90:4212–4220. 2018.
View Article : Google Scholar
|
|
69
|
Wang J, Li Y, Wang R, Han C, Xu S, You T,
Li Y, Xia J, Xu X, Wang D, et al: A fully automated and integrated
microfluidic system for efficient CTC detection and its application
in hepatocellular carcinoma screening and prognosis. ACS Appl Mater
Interfaces. 13:30174–30186. 2021. View Article : Google Scholar
|
|
70
|
Lee J and Kwak B: Simultaneous on-chip
isolation and characterization of circulating tumor cell
sub-populations. Biosens Bioelectron. 168:1125642020. View Article : Google Scholar
|
|
71
|
Lee AC, Svedlund J, Darai E, Lee Y, Lee D,
Lee HB, Kim SM, Kim O, Bae HJ, Choi A, et al: OPENchip: An on-chip
in situ molecular profiling platform for gene expression analysis
and oncogenic mutation detection in single circulating tumour
cells. Lab Chip. 20:912–922. 2020. View Article : Google Scholar
|
|
72
|
Zhang Y, Li M, Gao X, Chen Y and Liu T:
Nanotechnology in cancer diagnosis: Progress, challenges and
opportunities. J Hematol Oncol. 12:1372019. View Article : Google Scholar
|
|
73
|
Huang Q, Yin W, Chen X, Wang Y, Li Z, Du
S, Wang L and Shi C: Nanotechnology-based strategies for early
cancer diagnosis using circulating tumor cells as a liquid biopsy.
Nanotheranostics. 2:21–41. 2018. View Article : Google Scholar
|
|
74
|
Muthu MS and Feng SS: Theranostic
liposomes for cancer diagnosis and treatment: Current development
and pre-clinical success. Expert Opin Drug Deliv. 10:151–155. 2013.
View Article : Google Scholar
|
|
75
|
Lin D, Shen L, Luo M, Zhang K, Li J, Yang
Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor
cells: Biology and clinical significance. Sig Transduct Target
Ther. 6:4042021. View Article : Google Scholar
|
|
76
|
Hüsemann Y, Geigl JB, Schubert F, Musiani
P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G and
Klein CA: Systemic spread is an early step in breast cancer. Cancer
Cell. 13:58–68. 2008. View Article : Google Scholar
|
|
77
|
Hosseini H, Obradović MMS, Hoffmann M,
Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C,
Maneck M, et al: Early dissemination seeds metastasis in breast
cancer. Nature. 540:552–558. 2016. View Article : Google Scholar
|
|
78
|
Rhim AD, Thege FI, Santana SM, Lannin TB,
Saha TN, Tsai S, Maggs LR, Kochman ML, Ginsberg GG, Lieb JG, et al:
Detection of circulating pancreas epithelial cells in patients with
pancreatic cystic lesions. Gastroenterology. 146:647–651. 2014.
View Article : Google Scholar
|
|
79
|
Yamaguchi J, Kokuryo T, Yokoyama Y, Ebata
T, Ochiai Y and Nagino M: Premalignant pancreatic cells seed
stealth metastasis in distant organs in mice. Oncogene.
40:2273–2284. 2021. View Article : Google Scholar
|
|
80
|
Banys M, Hahn M, Gruber I, Krawczyk N,
Wallwiener M, Hartkopf A, Taran FA, Röhm C, Kurth R, Becker S, et
al: Detection and clinical relevance of hematogenous tumor cell
dissemination in patients with ductal carcinoma in situ. Breast
Cancer Res Treat. 144:531–538. 2014. View Article : Google Scholar
|
|
81
|
Shao X, Jin X, Chen Z, Zhang Z, Chen W,
Jiang J, Wang Z, Cui Y, Fan WH, Wang K, et al: A comprehensive
comparison of circulating tumor cells and breast imaging modalities
as screening tools for breast cancer in Chinese women. Front Oncol.
12:8902482022. View Article : Google Scholar
|
|
82
|
Ignatiadis M, Rothé F, Chaboteaux C,
Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal
SK, Michiels S, et al: HER2-positive circulating tumor cells in
breast cancer. PLoS One. 6:e156242011. View Article : Google Scholar
|
|
83
|
Thery L, Meddis A, Cabel L, Proudhon C,
Latouche A, Pierga JY and Bidard FC: Circulating tumor cells in
early breast cancer. JNCI Cancer Spectr. 3:pkz0262019. View Article : Google Scholar
|
|
84
|
Bidard FC, Michiels S, Riethdorf S,
Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J,
Gisbert-Criado R, Sleijfer S, et al: Circulating tumor cells in
breast cancer patients treated by neoadjuvant chemotherapy: A
meta-analysis. J Natl Cancer Inst. 110:560–567. 2018. View Article : Google Scholar
|
|
85
|
Rack B, Schindlbeck C, Jückstock J,
Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H,
Fasching PA, et al: Circulating tumor cells predict survival in
early average-to-high risk breast cancer patients. J Natl Cancer
Inst. 106:dju0662014. View Article : Google Scholar
|
|
86
|
Janni WJ, Rack B, Terstappen LWMM, Pierga
JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, et
al: Pooled analysis of the prognostic relevance of circulating
tumor cells in primary breast cancer. Clin Cancer Res.
22:2583–2593. 2016. View Article : Google Scholar
|
|
87
|
Pierga JY, Bidard FC, Mathiot C, Brain E,
Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A
and Marty M: Circulating tumor cell detection predicts early
metastatic relapse after neoadjuvant chemotherapy in large operable
and locally advanced breast cancer in a phase II randomized trial.
Clin Cancer Res. 14:7004–7010. 2008. View Article : Google Scholar
|
|
88
|
Hall C, Karhade M, Laubacher B, Anderson
A, Kuerer H, DeSynder S and Lucci A: Circulating tumor cells after
neoadjuvant chemotherapy in stage I–III triple-negative breast
cancer. Ann Surg Oncol. 22 (Suppl 3):S552–S558. 2015. View Article : Google Scholar
|
|
89
|
Hwang SB, Bae JW, Lee HY and Kim HY:
Circulating tumor cells detected by RT-PCR for CK-20 before surgery
indicate worse prognostic impact in triple-negative and HER2
subtype breast cancer. J Breast Cancer. 15:34–42. 2012. View Article : Google Scholar
|
|
90
|
Azim HA Jr, Rothé F, Aura CM, Bavington M,
Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, et
al: Circulating tumor cells and response to neoadjuvant paclitaxel
and HER2-targeted therapy: A sub-study from the NeoALTTO phase III
trial. Breast. 22:1060–1065. 2013. View Article : Google Scholar
|
|
91
|
Onstenk W, Kraan J, Mostert B, Timmermans
MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S,
Heijns JB, et al: Improved circulating tumor cell detection by a
combined EpCAM and MCAM cellsearch enrichment approach in patients
with breast cancer undergoing neoadjuvant chemotherapy. Mol Cancer
Ther. 14:821–827. 2015. View Article : Google Scholar
|
|
92
|
Kasimir-Bauer S, Bittner AK, König L,
Reiter K, Keller T, Kimmig R and Hoffmann O: Does primary
neoadjuvant systemic therapy eradicate minimal residual disease?
Analysis of disseminated and circulating tumor cells before and
after therapy. Breast Cancer Res. 18:202016. View Article : Google Scholar
|
|
93
|
Pierga JY, Bidard FC, Autret A, Petit T,
Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, et
al: Circulating tumour cells and pathological complete response:
Independent prognostic factors in inflammatory breast cancer in a
pooled analysis of two multicentre phase II trials (BEVERLY-1 and
−2) of neoadjuvant chemotherapy combined with bevacizumab. Ann
Oncol. 28:103–109. 2017. View Article : Google Scholar
|
|
94
|
Riethdorf S, Müller V, Loibl S, Nekljudova
V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, et
al: Prognostic impact of circulating tumor cells for breast cancer
patients treated in the neoadjuvant ‘Geparquattro’ trial. Clin
Cancer Res. 23:5384–5393. 2017. View Article : Google Scholar
|
|
95
|
Bidard FC, Mathiot C, Delaloge S, Brain E,
Giachetti S, de Cremoux P, Marty M and Pierga JY: Single
circulating tumor cell detection and overall survival in
nonmetastatic breast cancer. Ann Oncol. 21:729–733. 2009.
View Article : Google Scholar
|
|
96
|
Bidard FC, Belin L, Delaloge S, Lerebours
F, Ngo C, Reyal F, Alran S, Giacchetti S, Marty M, Lebofsky R and
Pierga JY: Time-dependent prognostic impact of circulating tumor
cells detection in non-metastatic breast cancer: 70-Month analysis
of the REMAGUS02 study. Int J Breast Cancer. 2013:1304702013.
View Article : Google Scholar
|
|
97
|
Riethdorf S, Müller V, Zhang L, Rau T,
Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, et al:
Detection and HER2 expression of circulating tumor cells:
Prospective monitoring in breast cancer patients treated in the
neoadjuvant GeparQuattro trial. Clin Cancer Res. 16:2634–2645.
2010. View Article : Google Scholar
|
|
98
|
Sparano J, O'Neill A, Alpaugh K, Wolff AC,
Northfelt DW, Dang CT, Sledge GW and Miller KD: Association of
circulating tumor cells with late recurrence of estrogen
receptor-positive breast cancer: A secondary analysis of a
randomized clinical trial. JAMA Oncol. 4:1700–1706. 2018.
View Article : Google Scholar
|
|
99
|
Janni W, Rack BK, Fasching PA, Haeberle L,
Tesch H, Lorenz R, Schochter F, Tzschaschel M, De Gregorio A, Fehm
TN, et al: Persistence of circulating tumor cells in high risk
early breast cancer patients five years after adjuvant chemotherapy
and late recurrence: Results from the adjuvant SUCCESS A trial. J
Clin Oncol. 36 (Suppl):S5152018. View Article : Google Scholar
|
|
100
|
Trapp E, Janni W, Schindlbeck C, Jückstock
J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M,
Polasik A, Koch JG, et al: Presence of circulating tumor cells in
high-risk early breast cancer during follow-up and prognosis. J
Natl Cancer Inst. 111:380–387. 2019. View Article : Google Scholar
|
|
101
|
Bidard FC, Fehm T, Ignatiadis M, Smerage
JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V,
Hayes DF, et al: Clinical application of circulating tumor cells in
breast cancer: Overview of the current interventional trials.
Cancer Metastasis Rev. 32:179–188. 2013. View Article : Google Scholar
|
|
102
|
Hall CS, Karhade MG, Bowman Bauldry JB,
Valad LM, Kuerer HM, DeSnyder SM and Lucci A: Prognostic value of
circulating tumor cells identified before surgical resection in
nonmetastatic breast cancer patients. J Am Coll Surg. 223:20–29.
2016. View Article : Google Scholar
|
|
103
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar
|
|
104
|
Walter VP, Taran FA, Wallwiener M, Hahn M,
Brucker SY and Hartkopf AD: Simultaneous detection of circulating
and disseminated tumor cells in primary breast cancer patients
following neoadjuvant chemotherapy. Arch Gynecol Obstet.
297:785–790. 2018. View Article : Google Scholar
|
|
105
|
Peeters DJE, van Dam PJ, Van den Eynden
GGM, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere
SJ, van Dam PA, et al: Detection and prognostic significance of
circulating tumour cells in patients with metastatic breast cancer
according to immunohistochemical subtypes. Br J Cancer.
110:375–383. 2014. View Article : Google Scholar
|
|
106
|
Giordano A, Giuliano M, Hsu L, Handy BC,
Ueno NT, Andreopoulou E, Alvarez RH, Valero V, Hortobagyi GN and
Cristofanilli M: Prognostic value of circulating tumor cells (CTC)
in metastatic breast cancer (MBC): Correlation with
immunohistochemically defined molecular subtypes and metastatic
disease sites. J Clin Oncol. 28 (Suppl):S10002010. View Article : Google Scholar
|
|
107
|
Budd GT, Cristofanilli M, Ellis MJ,
Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV,
Terstappen LW and Hayes DF: Circulating tumor cells versus
imaging-predicting overall survival in metastatic breast cancer.
Clin Cancer Res. 12:6403–6409. 2006. View Article : Google Scholar
|
|
108
|
Giuliano M, Giordano A, Jackson S, Hess
KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De
Laurentiis M, et al: Circulating tumor cells as prognostic and
predictive markers in metastatic breast cancer patients receiving
first-line systemic treatment. Breast Cancer Res. 13:R672011.
View Article : Google Scholar
|
|
109
|
Giordano A, Giuliano M, De Laurentiis M,
Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH,
Valero V, et al: Circulating tumor cells in immunohistochemical
subtypes of metastatic breast cancer: Lack of prediction in
HER2-positive disease treated with targeted therapy. Ann Oncol.
23:1144–1150. 2012. View Article : Google Scholar
|
|
110
|
Bidard FC, Peeters DJ, Fehm T, Nolé F,
Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz
JA, Stebbing J, et al: Clinical validity of circulating tumour
cells in patients with metastatic breast cancer: A pooled analysis
of individual patient data. Lancet Oncol. 15:406–414. 2014.
View Article : Google Scholar
|
|
111
|
Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C
and Mao Y: Prognostic value of circulating tumor cells in
metastatic breast cancer: A systemic review and meta-analysis. Clin
Transl Oncol. 18:322–330. 2016. View Article : Google Scholar
|
|
112
|
Hayes DF, Cristofanilli M, Budd GT, Ellis
MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and
Terstappen LW: Circulating tumor cells at each follow-up time point
during therapy of metastatic breast cancer patients predict
progression-free and overall survival. Clin Cancer Res.
12:4218–4224. 2006. View Article : Google Scholar
|
|
113
|
Cristofanilli M, Broglio KR, Guarneri V,
Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara
JM, et al: Circulating tumor cells in metastatic breast cancer:
Biologic staging beyond tumor burden. Clin Breast Cancer.
7:471–479. 2007. View Article : Google Scholar
|
|
114
|
Bidard FC, Vincent-Salomon A,
Sigal-Zafrani B, Diéras V, Mathiot C, Mignot L, Thiery JP,
Sastre-Garau X and Pierga JY: Prognosis of women with stage IV
breast cancer depends on detection of circulating tumor cells
rather than disseminated tumor cells. Ann Oncol. 19:496–500. 2008.
View Article : Google Scholar
|
|
115
|
Yagata H, Nakamura S, Toi M, Bando H, Ohno
S and Kataoka A: Evaluation of circulating tumor cells in patients
with breast cancer: Multi-institutional clinical trial in Japan.
Int J Clin Oncol. 13:252–256. 2008. View Article : Google Scholar
|
|
116
|
De Giorgi U, Valero V, Rohren E, Dawood S,
Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC,
et al: Circulating tumor cells and [18F]fluorodeoxyglucose positron
emission tomography/computed tomography for outcome prediction in
metastatic breast cancer. J Clin Oncol. 27:3303–3311. 2009.
View Article : Google Scholar
|
|
117
|
Liu MC, Shields PG, Warren RD, Cohen P,
Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J,
Seillier-Moiseiwitsch F, Noone AM and Isaacs C: Circulating tumor
cells: A useful predictor of treatment efficacy in metastatic
breast cancer. J Clin Oncol. 27:5153–5159. 2009. View Article : Google Scholar
|
|
118
|
Mego M, De Giorgi U, Hsu L, Ueno NT,
Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM and
Cristofanilli M: Circulating tumor cells in metastatic inflammatory
breast cancer. Annals Oncol. 20:1824–1828. 2009. View Article : Google Scholar
|
|
119
|
De Giorgi U, Valero V, Rohren E, Mego M,
Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA,
et al: Circulating tumor cells and bone metastases as detected by
FDG-PET/CT in patients with metastatic breast cancer. Annals Oncol.
21:33–39. 2010. View Article : Google Scholar
|
|
120
|
Consoli F, Grisanti S, Amoroso V, Almici
C, Verardi R, Marini M and Simoncini E: Circulating tumor cells as
predictors of prognosis in metastatic breast cancer: Clinical
application outside a clinical trial. Tumori. 97:737–742. 2011.
View Article : Google Scholar
|
|
121
|
Hartkopf AD, Wagner P, Wallwiener D, Fehm
T and Rothmund R: Changing levels of circulating tumor cells in
monitoring chemotherapy response in patients with metastatic breast
cancer. Anticancer Res. 31:979–984. 2011.
|
|
122
|
Tokudome N, Ito Y, Takahashi S, Kobayashi
K, Taira S, Tsutsumi C, Oto M, Oba M, Inoue K, Kuwayama A, et al:
Detection of circulating tumor cells in peripheral blood of heavily
treated metastatic breast cancer patients. Breast Cancer.
18:195–202. 2011. View Article : Google Scholar
|
|
123
|
De Giorgi U, Mego M, Scarpi E, Giuliano M,
Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN and
Cristofanilli M: Relationship between lymphocytopenia and
circulating tumor cells as prognostic factors for overall survival
in metastatic breast cancer. Clin Breast Cancer. 12:264–269. 2012.
View Article : Google Scholar
|
|
124
|
Hayashi N, Nakamura S, Tokuda Y, Shimoda
Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M and
Ueno NT: Prognostic value of HER2-positive circulating tumor cells
in patients with metastatic breast cancer. Int J Clin Oncol.
17:96–104. 2012. View Article : Google Scholar
|
|
125
|
Pierga JY, Hajage D, Bachelot T, Delaloge
S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C and
Bidard FC: High independent prognostic and predictive value of
circulating tumor cells compared with serum tumor markers in a
large prospective trial in first-line chemotherapy for metastatic
breast cancer patients. Annals Oncol. 23:618–624. 2012. View Article : Google Scholar
|
|
126
|
Weissenstein U, Schumann A, Reif M, Link
S, Toffol-Schmidt UD and Heusser P: Detection of circulating tumor
cells in blood of metastatic breast cancer patients using a
combination of cytokeratin and EpCAM antibodies. BMC Cancer.
12:2062012. View Article : Google Scholar
|
|
127
|
Jiang ZF, Cristofanilli M, Shao ZM, Tong
ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, et al:
Circulating tumor cells predict progression-free and overall
survival in Chinese patients with metastatic breast cancer,
HER2-positive or triple-negative (CBCSG004): A multicenter,
double-blind, prospective trial. Annals Oncol. 24:2766–2772. 2013.
View Article : Google Scholar
|
|
128
|
Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu
H, Li S, Hu Z, Wu S, Liu B and Jiang Z: Circulating tumor cells in
HER2-positive metastatic breast cancer patients: A valuable
prognostic and predictive biomarker. BMC Cancer. 13:2022013.
View Article : Google Scholar
|
|
129
|
Tarhan MO, Gonel A, Kucukzeybek Y, Erten
C, Cuhadar S, Yigit SC, Atay A, Somali I, Dirican A, Demir L and
Koseoglu M: Prognostic significance of circulating tumor cells and
serum CA15-3 levels in metastatic breast cancer, single center
experience, preliminary results. Asian Pac J Cancer Prev.
14:1725–1729. 2013. View Article : Google Scholar
|
|
130
|
Turker I, Uyeturk U, Sonmez OU, Oksuzoglu
B, Helvaci K, Arslan UY, Budakoglu B, Alkis N, Aksoy S and Zengin
N: Detection of circulating tumor cells in breast cancer patients:
Prognostic predictive role. Asian Pac J Cancer Prev. 14:1601–1607.
2013. View Article : Google Scholar
|
|
131
|
Wallwiener M, Hartkopf AD, Baccelli I,
Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B,
et al: The prognostic impact of circulating tumor cells in subtypes
of metastatic breast cancer. Breast Cancer Res Treat. 137:503–510.
2013. View Article : Google Scholar
|
|
132
|
Cristofanilli M, Pierga JY, Reuben J,
Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado
R, Mavroudis D, et al: The clinical use of circulating tumor cells
(CTCs) enumeration for staging of metastatic breast cancer (MBC):
International expert consensus paper. Crit Rev Oncol Hematol.
134:39–45. 2019. View Article : Google Scholar
|
|
133
|
Magbanua MJM, Hendrix LH, Hyslop T, Barry
WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga
JY, et al: Serial analysis of circulating tumor cells in metastatic
breast cancer receiving first-line chemotherapy. J Natl Cancer
Inst. 113:443–452. 2021. View Article : Google Scholar
|
|
134
|
Sundling KE and Lowe AC: Circulating tumor
cells: Overview and opportunities in cytology. Adv Anat Pathol.
26:56–63. 2019. View Article : Google Scholar
|
|
135
|
Larsson AM, Jansson S, Bendahl PO, Levin
Tykjaer Jörgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K
and Rydén L: Longitudinal enumeration and cluster evaluation of
circulating tumor cells improve prognostication for patients with
newly diagnosed metastatic breast cancer in a prospective
observational trial. Breast Cancer Res. 20:482018. View Article : Google Scholar
|
|
136
|
Jauch SF, Riethdorf S, Sprick MR, Schütz
F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker
LM, et al: Sustained prognostic impact of circulating tumor cell
status and kinetics upon further progression of metastatic breast
cancer. Breast Cancer Res. Treat. 173:155–165. 2019.
|
|
137
|
Cabel L, Berger F, Cottu P, Loirat D,
Rampanou A, Brain E, Cyrille S, Bourgeois H, Kiavue N, Deluche E,
et al: Clinical utility of circulating tumour cell-based monitoring
of late-line chemotherapy for metastatic breast cancer: The
randomised CirCe01 trial. Br J Cancer. 124:1207–1213. 2021.
View Article : Google Scholar
|
|
138
|
Smerage JB, Barlow WE, Hortobagyi GN,
Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF,
O'Rourke MA, Lew DL, et al: Circulating tumor cells and response to
chemotherapy in metastatic breast cancer: SWOG S0500. J Clin oncol.
32:3483–3489. 2014. View Article : Google Scholar
|
|
139
|
Bidard FC, Jacot W, Kiavue N, Dureau S,
Kadi A, Brain E, Bachelot T, Bourgeois H, Gonçalves A, Ladoire S,
et al: Efficacy of circulating tumor cell count-driven vs
clinician-driven first-line therapy choice in hormone
receptor-positive, ERBB2-negative metastatic breast cancer: The
STIC CTC randomized clinical trial. JAMA Oncol. 7:34–41. 2021.
View Article : Google Scholar
|
|
140
|
Jacot W, Cottu P, Berger F, Dubot C,
Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V,
Luporsi E, et al: Actionability of HER2-amplified circulating tumor
cells in HER2-negative metastatic breast cancer: The CirCe T-DM1
trial. Breast Cancer Res. 21:1212019. View Article : Google Scholar
|
|
141
|
Fehm T, Müller V, Banys-Paluchowski M,
Fasching PA, Friedl TWP, Hartkopf AD, Huober J, Loehberg C, Rack B,
Riethdorf S, et al: Abstract PD3-12: Efficacy of the tyrosine
kinase inhibitor lapatinib in the treatment of patients with
HER2-negative metastatic breast cancer and HER2-positive
circulating tumor cells-results from the randomized phase III
DETECT III trial. Cancer Res. 81 (4 Suppl):PD3–12. 2021. View Article : Google Scholar
|
|
142
|
Amir E, Miller N, Geddie W, Freedman O,
Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G,
Laupacis A, et al: Prospective study evaluating the impact of
tissue confirmation of metastatic disease in patients with breast
cancer. J Clin Oncol. 30:587–592. 2012. View Article : Google Scholar
|
|
143
|
Simmons C, Miller N, Geddie W, Gianfelice
D, Oldfield M, Dranitsaris G and Clemons MJ: Does confirmatory
tumor biopsy alter the management of breast cancer patients with
distant metastases? Ann Oncol. 20:1499–1504. 2009. View Article : Google Scholar
|
|
144
|
Thompson AM, Jordan LB, Quinlan P,
Anderson E, Skene A, Dewar JA and Purdie CA; Breast Recurrence in
Tissues Study Group, : Prospective comparison of switches in
biomarker status between primary and recurrent breast cancer: The
breast recurrence in tissues study (BRITS). Breast Cancer Res.
12:R922010. View Article : Google Scholar
|
|
145
|
Curigliano G, Bagnardi V, Viale G,
Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici
S, Bellomi M, et al: Should liver metastases of breast cancer be
biopsied to improve treatment choice? Ann Oncol. 22:2227–2233.
2011. View Article : Google Scholar
|
|
146
|
Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM
and Sneige N: Stability of HER2-positive status in breast
carcinoma: A comparison between primary and paired metastatic
tumors with regard to the possible impact of intervening
trastuzumab treatment. Ann Oncol. 22:1547–1553. 2011. View Article : Google Scholar
|
|
147
|
Sari E, Guler G, Hayran M, Gullu I,
Altundag K and Ozisik Y: Comparative study of the
immunohistochemical detection of hormone receptor status and HER-2
expression in primary and paired recurrent/metastatic lesions of
patients with breast cancer. Med Oncol. 28:57–63. 2011. View Article : Google Scholar
|
|
148
|
Amir E, Clemons M, Purdie CA, Miller N,
Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB and
Thompson AM: Tissue confirmation of disease recurrence in breast
cancer patients: Pooled analysis of multi-centre,
multi-disciplinary prospective studies. Cancer Treat Rev.
38:708–714. 2012. View Article : Google Scholar
|
|
149
|
Chang HJ, Han SW, Oh DY, Im SA, Jeon YK,
Park IA, Han W, Noh DY, Bang YJ and Kim TY: Discordant human
epidermal growth factor receptor 2 and hormone receptor status in
primary and metastatic breast cancer and response to trastuzumab.
Jpn J Clin Oncol. 41:593–599. 2011. View Article : Google Scholar
|
|
150
|
Dieci MV, Barbieri E, Piacentini F,
Ficarra G, Bettelli S, Dominici M, Conte PF and Guarneri V:
Discordance in receptor status between primary and recurrent breast
cancer has a prognostic impact: A single-institution analysis. Ann
Oncol. 24:101–108. 2013. View Article : Google Scholar
|
|
151
|
Lindström LS, Karlsson E, Wilking UM,
Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L and Bergh
J: Clinically used breast cancer markers such as estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2
are unstable throughout tumor progression. J Clin Oncol.
30:2601–2608. 2012. View Article : Google Scholar
|
|
152
|
Alix-Panabières C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar
|
|
153
|
Schochter F, Friedl TWP, deGregorio A,
Krause S, Huober J, Rack B and Janni W: Are circulating tumor cells
(CTCs) ready for clinical use in breast cancer? An overview of
completed and ongoing trials using CTCs for clinical treatment
decisions. Cells. 8:14122019. View Article : Google Scholar
|
|
154
|
Müller V, Banys-Paluchowski M, Friedl TWP,
Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B,
Meier-Stiegen F, Huober J, et al: Prognostic relevance of the HER2
status of circulating tumor cells in metastatic breast cancer
patients screened for participation in the DETECT study program.
ESMO Open. 6:1002992021. View Article : Google Scholar
|
|
155
|
Paoletti C, Regan MM, Liu MC, Marcom PK,
Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, et
al: Abstract P1-01-01: Circulating tumor cell number and
CTC-endocrine therapy index predict clinical outcomes in ER
positive metastatic breast cancer patients: Results of the COMETI
phase 2 trial. Cancer Res. 77 (4 Suppl):P1-01-01. 2017. View Article : Google Scholar
|
|
156
|
Salu P and Reindl KM: Advancements in
circulating tumor cell research: Bridging biology and clinical
applications. Cancers (Basel). 16:12132024. View Article : Google Scholar
|
|
157
|
Smit DJ, Schneegans S and Pantel K:
Clinical applications of circulating tumor cells in patients with
solid tumors. Clin Exp Metastasis. 41:403–411. 2024. View Article : Google Scholar
|
|
158
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual (7th ed). New
York, NY: Springer; 2010
|
|
159
|
Cabel L, Proudhon C, Gortais H, Loirat D,
Coussy F, Pierga JY and Bidard FC: Circulating tumor cells:
Clinical validity and utility. Int J Clin Oncol. 22:421–430. 2017.
View Article : Google Scholar
|
